UBS Group’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-2,305,123
| Closed | -$49.4M | – | 10543 |
|
|
2026
Q1 | $49.4M | Buy |
2,305,123
+2,134,395
| +1,250% | +$30.1M | 0.01% | 1655 |
|
|
2025
Q4 | $1.59M | Sell |
170,728
-38,989
| -19% | -$326K | ﹤0.01% | 5170 |
|
|
2025
Q3 | $1.48M | Buy |
209,717
+120,242
| +134% | +$827K | ﹤0.01% | 5245 |
|
|
2025
Q2 | $582K | Sell |
89,475
-34,701
| -28% | -$239K | ﹤0.01% | 5881 |
|
|
2025
Q1 | $985K | Buy |
124,176
+59,949
| +93% | +$646K | ﹤0.01% | 5299 |
|
|
2024
Q4 | $814K | Sell |
64,227
-50,410
| -44% | -$701K | ﹤0.01% | 5470 |
|
|
2024
Q3 | $1.6M | Buy |
114,637
+44,554
| +64% | +$636K | ﹤0.01% | 4221 |
|
|
2024
Q2 | $966K | Sell |
70,083
-93,935
| -57% | -$1.37M | ﹤0.01% | 4453 |
|
|
2024
Q1 | $2.71M | Buy |
164,018
+37,378
| +30% | +$559K | ﹤0.01% | 3631 |
|
|
2023
Q4 | $1.85M | Buy |
126,640
+102,759
| +430% | +$1.25M | ﹤0.01% | 3914 |
|
|
2023
Q3 | $293K | Buy |
23,881
+11,338
| +90% | +$148K | ﹤0.01% | 5070 |
|
|
2023
Q2 | $150K | Sell |
12,543
-57,322
| -82% | -$749K | ﹤0.01% | 5683 |
|
|
2023
Q1 | $934K | Sell |
69,865
-59,992
| -46% | -$1.17M | ﹤0.01% | 4168 |
|
|
2022
Q4 | $2.79M | Buy |
129,857
+108,251
| +501% | +$2.22M | ﹤0.01% | 3044 |
|
|
2022
Q3 | $432K | Buy |
21,606
+17,755
| +461% | +$378K | ﹤0.01% | 4468 |
|
|
2022
Q2 | $69K | Buy |
+3,851
| New | +$39.8K | ﹤0.01% | 5688 |
|
|
2022
Q1 | – | Sell |
-6,103
| Closed | -$103K | – | 10354 |
|
|
2021
Q4 | $103K | Buy |
6,103
+6,044
| +10,244% | +$124K | ﹤0.01% | 6293 |
|
|
2021
Q3 | $1K | Buy |
+59
| New | +$1.41K | ﹤0.01% | 9166 |
|
Other funds holding DAWN
UBS Group's DAWN Position: Q2 2026 in Review
UBS Group sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 2,305,123 shares — an estimated $49.4M sold.
UBS Group first reported a position in DAWN in Q3 2021 and held it in 18 quarters. The position peaked at $49.4M in Q1 2026. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- UBS Group reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 2,305,123 Day One Biopharmaceuticals shares in Q2 2026, an estimated $49.4M.
- UBS Group first reported a position in Day One Biopharmaceuticals in Q3 2021 and held it in 18 quarters.
- UBS Group's Day One Biopharmaceuticals position peaked at $49.4M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.